Insider · CIK 0001336503

KANGO SUJAY

Reports to the SEC for 4 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001336503

Forms 4 and 5

Insider transactions

49 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-21	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director	AAward	+6,090 sh	—	—	6,090
2025-03-04	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2023-09-29	LITSLite Strategy, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2022-07-05	LITSLite Strategy, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+87.5K sh	—	—	87,500
2022-03-30	INFINITY PHARMACEUTICALS, INC.Stock Option (right to buy)A Award	Director	AAward	+90K sh	—	—	90,000
2021-11-22	LITSLite Strategy, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+58.3K sh	—	—	58,334
2021-11-19	ACCELERON PHARMA INCU Disposition from Tender	EVP, Chief Commercial Officer	UDisposition from Tender	−18.5K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−25K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−25.5K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−24.3K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−20.9K sh	—	—	0
2021-09-27	ACCELERON PHARMA INCM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+5,000 sh	$40.61	+$203K	23,509
2021-09-27	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−5,000 sh	$175.00	−$875K	18,509
2021-09-27	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−5,000 sh	—	—	25,000
2021-09-21	ACCELERON PHARMA INCM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+5,000 sh	$40.61	+$203K	23,509
2021-09-21	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−5,000 sh	$150.03	−$750K	18,509
2021-09-21	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−5,000 sh	—	—	30,000
2021-03-02	ACCELERON PHARMA INCM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+5,000 sh	$40.61	+$203K	24,396
2021-03-02	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−2,699 sh	$135.48	−$366K	21,697
2021-03-02	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−1,501 sh	$136.24	−$204K	20,196
2021-03-02	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−600 sh	$137.12	−$82.3K	19,596
2021-03-02	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−200 sh	$138.15	−$27.6K	19,396
2021-03-02	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−5,000 sh	—	—	35,000
2021-02-12	ACCELERON PHARMA INCF Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−887 sh	$130.87	−$116K	18,509
2021-01-29	ACCELERON PHARMA INCA Award	EVP, Chief Commercial Officer	AAward	+5,409 sh	—	—	19,396
2021-01-29	ACCELERON PHARMA INCOption to Purchase Common StockA Award	EVP, Chief Commercial Officer	AAward	+20.9K sh	—	—	20,896
2021-01-04	ACCELERON PHARMA INCM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+10K sh	$40.61	+$406K	13,987
2021-01-04	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−10K sh	—	—	40,000
2021-01-04	ACCELERON PHARMA INCF Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−1,357 sh	$124.31	−$169K	13,987
2021-01-04	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−1,947 sh	$123.90	−$241K	12,040
2021-01-04	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−3,429 sh	$125.17	−$429K	8,611
2021-01-04	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−4,624 sh	$126.15	−$583K	3,987
2020-02-13	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−590 sh	$94.09	−$55.5K	15,349
2020-02-13	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−5 sh	$94.82	−$474.1	15,344
2020-01-22	ACCELERON PHARMA INCA Award	EVP, Chief Commercial Officer	AAward	+6,369 sh	—	—	15,939
2020-01-22	ACCELERON PHARMA INCOption to Purchase Common StockA Award	EVP, Chief Commercial Officer	AAward	+24.3K sh	—	—	24,334
2020-01-03	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−469 sh	$51.37	−$24.1K	9,581
2020-01-03	ACCELERON PHARMA INCS Sale	EVP, Chief Commercial Officer	SSale	−11 sh	$51.27	−$563.97	9,570
2019-01-25	ACCELERON PHARMA INCA Award	EVP, Chief Commercial Officer	AAward	+4,050 sh	—	—	10,050
2019-01-25	ACCELERON PHARMA INCOption to Purchase Common StockA Award	EVP, Chief Commercial Officer	AAward	+25.5K sh	—	—	25,500
2018-03-01	ACCELERON PHARMA INCOption to Purchase Common StockA Award	EVP, Chief Commercial Officer	AAward	+50K sh	—	—	50,000
2018-02-12	ACCELERON PHARMA INCA Award	EVP, Chief Commercial Officer	AAward	+6,000 sh	—	—	6,000
2016-12-13	INFINITY PHARMACEUTICALS, INC.S Sale	Director	SSale	−298 sh	$1.30	−$387.4	50,292
2016-12-13	INFINITY PHARMACEUTICALS, INC.S Sale	Director	SSale	−42K sh	$1.27	−$53.2K	8,275
2016-12-13	INFINITY PHARMACEUTICALS, INC.S Sale	Director	SSale	−7,676 sh	$1.25	−$9,623.401	599
2016-12-12	INFINITY PHARMACEUTICALS, INC.S Sale	Director	SSale	−25K sh	$1.30	−$32.6K	50,590
2016-10-31	INFINITY PHARMACEUTICALS, INC.A Award	Director	AAward	+75K sh	—	—	75,599
2016-01-06	INFINITY PHARMACEUTICALS, INC.Stock Option (right to buy)A Award	Director	AAward	+60K sh	—	—	60,000
2015-03-31	INFINITY PHARMACEUTICALS, INC.Stock Option (right to buy)A Award	Director	AAward	+200K sh	—	—	200,000

Recent filings

Accepted (ET)
May 224
KANGO SUJAY0001336503-26-000002
SEC(opens sec.gov)
Mar 54
KANGO SUJAY0000950170-25-033808
SEC(opens sec.gov)
Oct 124
KANGO SUJAY0000929638-23-002768
SEC(opens sec.gov)
Jul 74
KANGO SUJAY0001567619-22-013789
SEC(opens sec.gov)
Mar 314
KANGO SUJAY0001140361-22-012388
SEC(opens sec.gov)
Nov 234
KANGO SUJAY0001567619-21-021035
SEC(opens sec.gov)
Nov 224
KANGO SUJAY0001104659-21-142269
SEC(opens sec.gov)
Sep 274
KANGO SUJAY0001179110-21-008949
SEC(opens sec.gov)
Sep 224
KANGO SUJAY0001179110-21-008894
SEC(opens sec.gov)
Jun 84
KANGO SUJAY0001179110-21-006494
SEC(opens sec.gov)
Mar 44
KANGO SUJAY0001179110-21-002883
SEC(opens sec.gov)

Companies

Address

C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR

NEW YORK, NY, 10036